ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Ernexa Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 20 | Q3 20 | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | Q1 19 | Q4 18 | Q3 18 | Q2 18 | Q1 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subscription Revenue [Member] | $1.10M | $1.05M | $727.00K | $2.00M | $2.92M | $3.72M | $3.80M | $3.83M | $3.92M | $4.01M | $4.04M | $4.07M | 93.9% | -62.3% |
| Other Revenue [Member] | $67.00K | $45.00K | $1.00K | $379.00K | $707.00K | $846.00K | $831.00K | $794.00K | $837.00K | $841.00K | $1.02M | $1.02M | 5.7% | -90.5% |
| Hardware Revenue [Member] | $5.00K | $379.00K | $26.00K | $16.00K | $1.54M | $11.00K | $595.00K | $205.00K | $1.16M | $1.16M | $590.00K | $679.00K | 0.4% | -99.7% |
By region
| Revenue | Q4 20 | Q3 20 | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | Q1 19 | Q4 18 | Q3 18 | Q2 18 | Q1 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $1.09M | $1.42M | $722.00K | $2.25M | $5.01M | $4.42M | $5.06M | $4.66M | $5.75M | $5.83M | $5.48M | $5.59M | 92.8% | -78.2% |
| Canada [Member] | $85.00K | $57.00K | $32.00K | $145.00K | $159.00K | $160.00K | $163.00K | $171.00K | $172.00K | $171.00K | $169.00K | $169.00K | 7.2% | -46.5% |
From the segment and revenue-disaggregation notes of Ernexa Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.